LYON, France — Lerodalcibep, a novel, third-generation anti–proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, helps high-risk patients already receiving maximally tolerated statins to achieve guideline lipid targets, reported investigators.
In the randomized, placebo-controlled LIBerate-CVD trial of more than 900 patients, lerodalcibep led to reductions from baseline in low-density lipoprotein (LDL) cholesterol levels of more than 60%.
"We believe that lerodalcibep offers a novel, effective alternative to current PCSK9 inhibitors for patients with cardiovascular disease or at very high risk for cardiovascular disease," said Evan Stein, MD, PhD, chief scientific officer and cofounder of LIB Therapeutics in Chicago, who presented the findings here at the European Atherosclerosis Society (EAS) 2024.
Moreover, it leads to "substantial additional LDL cholesterol reductions on top of existing oral agents" and allows more than 90% of patients to achieve the latest European Society of Cardiology (ESC) guideline targets, he said.
Lerodalcibep has "tolerability and safety similar to placebo," Stein said, and requires only "a small monthly injection, which takes about 12 seconds."
"The drug doesn't require refrigeration" and is "stable, so far, over 9 months," he reported.
The latest data "confirm the efficacy of lerodalcibep," said Giuseppe Danilo Norata, PhD, from the Department of Pharmacological and Biomolecular Sciences at the University of Milan, Milan, Italy, who was not involved in the study.
The LDL cholesterol reduction in this phase 3 trial is "in line with what was observed in LIBerate-FH," and the high proportion of patients achieving their LDL cholesterol target is "impressive," he added.
Effective and Well Tolerated
The safety results are "suggestive of a drug that is well tolerated, with injection-site reactions being the only remarkable adverse event increased in the treatment group," Norata reported.
Only a "limited number" of patients developed neutralizing antidrug antibodies, which did not affect the efficacy of lerodalcibep. However, "given that the therapy is expected to be administered for years," a longer analysis is needed to exclude the concern that a small percentage of neutralizing antidrug antibodies could reduce the efficacy, he said.
If approved, lerodalcibep could end up as a first-line option in the treatment pathway for high-risk cardiovascular disease because the efficacy "is similar to that of other injectable PCSK9 inhibitors," he said, adding that its position in the market will "largely depend on the price."
As the mechanism of action is similar to that of other monoclonal antibodies, "there is no pharmacological rationale to use it after another PSCK9 inhibitor," he explained.
Lerodalcibep is a small recombinant fusion protein that combines a PCSK9-binding domain with human serum albumin.
The binding domain blocks the interaction between PCSK9 and the LDL cholesterol receptor, and the albumin linkage increases the half-life to 12-15 days, allowing low-volume injections to be given every 4 weeks.
A prior phase 2 study suggested that lerodalcibep substantially decreases LDL cholesterol levels in patients already taking maximally tolerated statins. The 300-mg dose was associated with an average reduction from baseline in LDL cholesterol levels of 77% over 12 weeks, whereas free PCSK9 levels decreased by 88%.
The current phase 3 study enrolled individuals at 65 centers in 100 countries who had or were at a very high risk for cardiovascular disease and who had an LDL cholesterol level of ≥ 1.8 mmol/L despite being on maximally tolerated statins.
Study participants were randomized in a 2:1 ratio to receive monthly subcutaneous lerodalcibep (n = 614) or placebo (n = 308) for 52 weeks and were assessed for the co-primary endpoints of the percentage change in LDL cholesterol levels from baseline to week 52 and the mean of levels at weeks 50 and 52.
The mean age was similar in the lerodalcibep and placebo groups (63.3 vs 64.5 years), as were the proportion of female (30% vs 30%) and White (80% vs 79%) participants.
The vast majority of participants in the lerodalcibep and placebo groups had a documented cardiovascular event (85.3% vs 86.4%) and were receiving secondary prevention, and 87% and 82%, respectively, were receiving a statin (any dose).
In a modified intention-to-treat analysis, the mean placebo-adjusted reduction in LDL cholesterol levels from baseline with lerodalcibep was 62% at week 52 (P < .0001), and the mean of levels at weeks 50 and 52 was 69.4% (P < .0001).
Similar results were seen in a per protocol analysis and an intention-to-treat analysis with imputation, which is a US Food and Drug Administration measure introduced in 2021 that assumes patients who discontinue the study treatment have an outcome similar to that in the placebo patients.
Moreover, 98.2% of patients in the lerodalicep group achieved the ESC and European Atherosclerosis Society recommended reduction in LDL cholesterol levels of ≥ 50%, whereas only 8.8% in the placebo group did.
Hitting the LDL Cholesterol Target
More patients in the lerodalicep group than in the placebo group achieved the LDL cholesterol target of < 1.4 mmol/L (95.3% vs 18.5%), and more patients in the lerodalicep group achieved both that target and the ≥ 50% target (94.5% and 6.8%).
Lerodalicep was also associated with significant reductions from baseline in levels of non–high-density lipoprotein (HDL) cholesterol, apolipoprotein B, Very LDL cholesterol, and triglycerides, as well as an increase in HDL cholesterol levels (P < .0001 for all).
In terms of safety, lerodalicep was associated with an adverse event rate leading to withdrawal similar to that seen with placebo (4.2% vs 3.6%), and 15.9% and 14.8% of patients, respectively, experienced at least one serious adverse event.
In-stent restenosis occurred more often in the lerodalicep group than in the placebo group (5.4% vs 2.0%).
The study drug was associated with low levels of transient and sporadic antidrug antibodies and a low rate of neutralizing antidrug antibodies (0.9%), which were not associated with restenosis, a reduction in free PCSK9 levels, or the ability of lerodalcibep to lower LDL cholesterol levels.